Abstract

Continuous operation allows process conditions that are not attainable within batch crystallizers to be utilized. This in turn allows for product crystal attributes that are not possible in the equivalent batch crystallizations to be produced. In this study, the product crystal size distributions attainable from the anti-solvent crystallization of benzoic acid in plug flow, MSMPR and the equivalent fed batch and batch reverse addition crystallizations, were characterized. It was found that the continuous plug flow and MSMPR crystallizers were able to access crystal size distributions that are both smaller and larger than could be produced via the equivalent batch crystallizations, in addition to providing huge increases in productivity.In-situ process analytical techniques (FBRM, ATR-FTIR) were employed to characterize each of these processes, including a calibration-free ATR-FTIR technique. Furthermore, a novel intermittent pneumatic MSMPR withdrawal method, which negated clogging/fouling of transfer lines, is demonstrated. It is hoped that the use of such techniques may facilitate the uptake of continuous processes in pharmaceutical crystallization where limitations on development time and concerns about slurry transport are perceived to be barriers to the implementation of this technology.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.